Migraine and headache:
Indications for: QULIPTA
Preventive treatment of episodic migraine.
Adult Dosage:
10mg, 30mg, or 60mg once daily. Concomitant strong CYP3A4 inhibitors: 10mg once daily. Concomitant strong or moderate CYP3A4 inducers: 30mg or 60mg once daily. Concomitant OATP inhibitors: 10mg or 30mg once daily. Severe renal impairment, ESRD: 10mg once daily.
Children Dosage:
Not established.
QULIPTA Warnings/Precautions:
Severe hepatic impairment: avoid. Severe renal impairment (CrCl 15–29mL/min), ESRD (CrCl <15mL/min): adjust dose; see Adult. ESRD on intermittent dialysis: give after session. Elderly. Pregnancy. Nursing mothers.
QULIPTA Classification:
Calcitonin gene-related peptide (CGRP) receptor antagonist.
QULIPTA Interactions:
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin) or OATP inhibitors (eg, cyclosporine, rifampin); adjust dose with concomitant use; see Adult. Antagonized by strong or moderate CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John's wort, efavirenz, etravirine); adjust dose with concomitant use; see Adult.
Adverse Reactions:
Nausea, constipation, fatigue.
Generic Drug Availability:
NO
How Supplied:
Tabs—30
